Savient Pharmaceuticals, Inc. Requests Two-Week Extension From NASDAQ Regarding Late Filings

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Dec. 22, 2005--Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that it has requested that the Nasdaq Listing Qualifications Panel (the Panel) extend until January 13, 2006 the date by which the Company must file amendments to its Form 10-K for the year ended December 31, 2004, including 2003 and 2002 prior period restatements, and Form 10-Q for the quarter ended March 31, 2005, as well as its initial Form 10-Q for the quarter ended June 30, 2005, in order to continue listing of the Company’s securities on the NASDAQ National Market. The Company also requested that the Panel extend until January 20, 2006 the date by which the Company must file its Form 10-Q for the quarter ended September 30, 2005. Previously, the Panel determined to continue the Company’s listing provided that the Company files amendments to its Form 10-K for the year ended December 31, 2004, including 2003 and 2002 prior period restatements, and Form 10-Q for the quarter ended March 31, 2005, as well as its initial Form 10-Q for the quarter ended June 30, 2005 by December 26, 2005, and files its Form 10-Q for the quarter ended September 30, 2005 on or before January 3, 2006.

MORE ON THIS TOPIC